浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Analysis of ADR reports caused by cefotaxime sodium in Shandong province and effects of skin test on serious ADR
- ZHONGGUO YAOFANG Vol. 34, Issue 10, Pages: 1233-1236(2023)
- 作者机构：
1.中国海洋大学医药学院，山东 青岛 266000
2.青岛市妇女儿童医院医院办公室，山东 青岛 266000
3.青岛市妇女儿童医院药学部，山东 青岛 266000
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.10.15
CLC： R978.1Published：30 May 2023，
Received：08 October 2022，
Revised：06 April 2023，
扫 描 看 全 文
任美娟,张红梅,刘畅等.山东省头孢噻肟钠致ADR报告分析及其皮试对严重的ADR的影响 Δ[J].中国药房,2023,34(10):1233-1236.
REN Meijuan,ZHANG Hongmei,LIU Chang,et al.Analysis of ADR reports caused by cefotaxime sodium in Shandong province and effects of skin test on serious ADR[J].ZHONGGUO YAOFANG,2023,34(10):1233-1236.
任美娟,张红梅,刘畅等.山东省头孢噻肟钠致ADR报告分析及其皮试对严重的ADR的影响 Δ[J].中国药房,2023,34(10):1233-1236. DOI： 10.6039/j.issn.1001-0408.2023.10.15.
REN Meijuan,ZHANG Hongmei,LIU Chang,et al.Analysis of ADR reports caused by cefotaxime sodium in Shandong province and effects of skin test on serious ADR[J].ZHONGGUO YAOFANG,2023,34(10):1233-1236. DOI： 10.6039/j.issn.1001-0408.2023.10.15.
摘要
目的
2
分析山东省头孢噻肟钠致药品不良反应（ADR）的临床表现及特点，探讨头孢噻肟钠用药前皮试对严重的ADR的影响，为临床安全用药提供参考。
方法
2
收集2019年12月－2021年12月山东省ADR监测中心上报国家ADR监测系统的头孢噻肟钠致ADR报告的相关数据，对报告涉及的ADR分类、患者年龄、性别、ADR发生时间、给药途径、患者过敏史、原患疾病、ADR累及系统/器官及临床表现、转归情况、用药前是否皮试等进行统计、分析。
结果
2
共纳入头孢噻肟钠致ADR报告1 057例。1 057例ADR中，一般的ADR有867例（82.02%），严重的ADR有190例（17.98%）；年龄以＜11岁为主（40.30%）；给药途径主要为静脉滴注（96.69%）；有1 033例患者（97.73%）为用药后＞30 min～24 h发生ADR；814例患者（77.01%）无过敏史；原患疾病以呼吸系统感染为主（56.58%）；ADR主要累及系统/器官为皮肤及附件、消化系统、呼吸系统，临床主要表现为皮疹、瘙痒、恶心、呕吐、胸闷等；经停药或对症治疗后，有1 050例患者（99.34%）痊愈或好转。850例患者在使用头孢噻肟钠前进行皮试（151例患者发生严重的ADR），与207例非皮试患者（39例患者发生严重的ADR）的严重的ADR发生率比较，差异无统计学意义（
P
＝0.718）。
结论
2
头孢噻肟钠致ADR主要以＜11岁患者为主，多发生在静脉滴注给药后＞30 min～24 h；头孢噻肟钠用药前皮试不能降低严重的ADR的发生风险。临床在使用头孢噻肟钠前应详细询问患者的过敏史、用药史，使用时应重点关注用药后24 h内患者的病情状态，防止严重的ADR发生，以保障患者的安全用药。
Abstract
OBJECTIVE
2
To analyze the clinical manifestations and characteristics of adverse drug reactions （ADR） caused by cefotaxime sodium in Shandong province， and to explore the effects of skin test before medication of cefotaxime sodium on serious ADR， so as to provide reference for safe drug use in clinic.
METHODS
2
The relevant data of cefotaxime sodium-induced ADR reported by Shandong Province ADR Monitoring Center during December 2019 to December 2021 were collected from National ADR Monitoring System. The ADR classification， age， gender， ADR occurrence time， route of administration， history of allergy， primary diseases， ADR systems/organs involved， clinical manifestations， outcome， skin test or not before medication were statistically analyzed.
RESULTS
2
A total of 1 057 ADR reports caused by cefotaxime sodium were included. Among them， there were 867 patients （82.02%） with general ADR and 190 patients （17.98%） with serious ADR. The majority were ＜11 years old （40.30%）. The main route of administration was intravenous drip （96.69%）. A total of 1 033 patients （97.73%） developed ADR 30 min to 24 h after medication. A total of 814 patients （77.01%） had no history of allergy. The primary diseases were respiratory system infection （56.58%）. Main systems/organs involved in ADR were skin and its appendants， digestive system and respiratory system， and its clinical manifestations were rash， pruritus， nausea， vomiting， chest tightness， etc. After withdrawal or symptomatic treatment， 1 050 patients （99.34%） were cured or improved. Before the use of cefotaxime sodium， 850 patients underwent skin test （151 patients occurred serious ADR）； there was no statistical significance in the incidence of serious ADR， compared with the incidence of serious ADR in 207 patients without skin test （39 patients occurred serious ADR） （
P
＝0.718）.
CONCLUSIONS
2
ADR caused by cefotaxime sodium is mainly seen in patients ＜11 years old， mostly occurring 30 min to 24 h after intravenous drip； skin test before medication of cefotaxime sodium cannot reduce the risk of serious ADR. Before using cefotaxime sodium in clinical practice， patients should be asked about their allergy and medication history in detail. During use， it is important to focus on the patient’s condition within 24 h after medication to prevent serious ADR and ensure the safety of clinical medication.
关键词
头孢噻肟钠不良反应用药安全山东省皮试
Keywords
adverse drug reactionssafety of drug useShandong provinceskin test
references
李国军，赵莹，姜天华，等. 头孢噻肟钠所致过敏反应文献概述[J]. 中国药物滥用防治杂志，2014，20（1）：59，50.
YOUNG L S. Review and reassessment of dosing sche-dules for cefotaxime in selected medical indications[J]. Diagn Microbiol Infect Dis，1995，22（1/2）：147-154.
PLOSKER G L，FOSTER R H，BENFIELD P. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections[J]. Pharmacoeconomics，1998，13（1 Pt 1）：91-106.
ROMANO A，GUÉANT-RODRIGUEZ R M，VIOLA M，et al. Diagnosing immediate reactions to cephalosporins[J]. Clin Exp Allergy，2005，35（9）：1234-1242.
薛智民，王荟. 注射用头孢噻肟儿科临床用药安全性分析[J]. 中国药物与临床，2021，21（17）：3027-3029.
国家卫生健康委员会. 《β内酰胺类抗菌药物皮肤试验指导原则（2021年版）》[EB/OL].（2021-04-13）[2022-05-01]. http：//www.nhc.gov.cn/yzygj/s7659/202104/a33f49b-8c4b5421c85a5649a28a0fce2.htmlhttp://www.nhc.gov.cn/yzygj/s7659/202104/a33f49b-8c4b5421c85a5649a28a0fce2.html.
中华人民共和国卫生部，国家药品监督管理局.药品不良反应报告和监测管理办法（卫生部令第81号）[EB/OL].（2011-05-04）[2023-03-30]. https：//www.nmpa.gov.cn/yaopin/ypfgwj/ypfgbmgzh/20110504162501325.htmlhttps://www.nmpa.gov.cn/yaopin/ypfgwj/ypfgbmgzh/20110504162501325.html.
赵赟，张东梅，姜旻，等. 头孢噻肟所致药品不良反应文献分析[J]. 中国药业，2021，30（6）：89-91.
范铭. 头孢曲松致儿童不良反应文献分析[J]. 儿科药学杂志，2021，27（3）：47-50.
蒋荣猛，宋美华. 关注特殊人群抗菌药物应用的安全性[J]. 药物不良反应杂志，2020，22（1）：2-5.
武福溶. 我区719例药品不良反应报告分析[J]. 海峡药学，2022，34（1）：216-217.
吕焕菊，李子民，刘莉莉，等. 头孢噻肟钠所致不良反应100例综合分析[J]. 中国冶金工业医学杂志，2009，26（5）：584-585.
宋燕梅，方雪云，江淑华. β-内酰胺类抗生素皮试假阴性的原因分析及预防[J]. 当代护士（中旬刊），2015（9）：108-110.
北京药学会抗生素专业委员会. 头孢类抗菌药物皮肤过敏试验高端论坛专家共识[J]. 临床药物治疗杂志，2008，6（4）：1-2.
杨建华，王松芝，胡君萍，等. 头孢噻肟钠皮试液稳定性考察[J]. 新疆医科大学学报，2001，24（4）：359-360.
梁欣，纪立伟. 头孢菌素类抗菌药物进行皮试问题的探讨[J]. 中国临床医生，2009，37（7）：60-61.
韩丽慧. 婴幼儿头孢菌素皮肤过敏试验结果临床观察[J]. 海峡药学，2010，22（10）：147-148.
徐丙发，武阿龙，黄健. 我院头孢菌素皮试情况及经济学分析[J]. 中国医药导报，2021，18（22）：46-49，66.
Pharmaceutical and Food Safety Bureau，Ministry of Health，Labour and Welfare. Pharmaceuticals and medical devices safety information No.206[EB/OL]. [2022-06-22]. https：//www.pmda.go.jp/files/000153622https://www.pmda.go.jp/files/000153622.
Pharmaceutical and Food Safety Bureau，Ministry of Health，Labour and Welfare. Pharmaceuticals and medical devices safety information No.264[EB/OL]. [2022-06-22]. https：//www.pmda.go.jp/files/000153193https://www.pmda.go.jp/files/000153193.
YANG M S，KANG D Y，SEO B，et al. Incidence of cephalosporin-induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins：a large multicenter retrospective cohort study[J]. Allergy，2018，73（9）：1833-1841.
张宏亮，李卉，刘滔滔，等. 广西某三甲医院取消头孢菌素类药物皮试实践[J/OL].中国医院药学杂志，2022：1-5[2022-06-22]. http：//kns.cnki.net/kcms/detail/42.1204.R.20220607.0950.002.htmlhttp://kns.cnki.net/kcms/detail/42.1204.R.20220607.0950.002.html.
KWON J W，KIM Y J，YANG M S，et al. Results of intradermal skin testing with cefazolin according to a history of hypersensitivity to antibiotics[J]. J Korean Med Sci，2019，34（50）：e319.
0
Views
13
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.